J.H. Whitney Equity Partners V Sells 12,496,077 Shares of Aveanna Healthcare (NASDAQ:AVAH) Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) major shareholder J.H. Whitney Equity Partners V sold 12,496,077 shares of Aveanna Healthcare stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $11.50, for a total value of $143,704,885.50. The transaction was disclosed in a document filed with the SEC, which is available through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

J.H. Whitney Equity Partners V also recently made the following trade(s):

• On Friday, August 21st, J.H. Whitney Equity Partners V sold 2,250,000 shares of Aveanna Healthcare stock. The shares were sold at an average price of $11.50, for a total value of $25,875,000.00.
• On Tuesday, June 30th, J.H. Whitney Equity Partners V sold 2,419,035 shares of Aveanna Healthcare stock. The stock was sold at an average price of $8.01, for a total value of $19,376,470.35.
• On Wednesday, June 24th, J.H. Whitney Equity Partners V sold 919,389 shares of Aveanna Healthcare stock. The stock was sold at an average price of $8.00, for a total value of $7,355,112.00.
• On Wednesday, June 3rd, J.H. Whitney Equity Partners V sold 5,842,240 shares of Aveanna Healthcare stock. The stock was sold at an average price of $6.24, for a total value of $36,455,577.60.

Aveanna Healthcare Trading Down 0.8%

Shares of Aveanna Healthcare stock opened at $13.59 on Wednesday. The firm has a 50-day moving average of $9.83 and a 200-day moving average of $7.99. The stock has a market cap of $2.97 billion, a PE ratio of 11.05, a PEG ratio of 0.96 and a beta of 1.90. Aveanna Healthcare Holdings Inc. has a 52-week low of $5.93 and a 52-week high of $13.98. The company has a debt-to-equity ratio of 4.47, a quick ratio of 1.16 and a current ratio of 1.16.

Aveanna Healthcare (NASDAQ:AVAH) last released its quarterly earnings results on Thursday, August 13th. The company reported $0.22 EPS for the quarter, topping analysts’ consensus estimates of $0.17 by $0.05. Aveanna Healthcare had a net margin of 10.56% and a return on equity of 80.70%. The business had revenue of $670.48 million for the quarter, compared to analyst estimates of $638.61 million. As a group, sell-side analysts forecast that Aveanna Healthcare Holdings Inc. will post 0.68 EPS for the current year.

Aveanna Healthcare News Summary

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Royal Bank of Canada raised its price target to $16 from $10 and upgraded AVAH to “outperform.” The upgrade reinforces the bullish outlook following the stock’s recent rally. Benzinga analyst coverage
• Positive Sentiment: Truist Financial increased its price target to $15 from $11, although it maintained a “hold” rating. Other analysts have also raised targets after Aveanna exceeded quarterly earnings and revenue expectations. Benzinga analyst coverage
• Positive Sentiment: Aveanna reported quarterly EPS of $0.22 versus the $0.17 consensus estimate and revenue of $670.48 million versus expectations of $638.61 million. The earnings beat supports the improved analyst outlook and investor interest in the shares.
• Neutral Sentiment: Management will participate in the Jefferies Healthcare Services and Technology Conference on September 15. The presentation and one-on-one investor meetings could provide additional business updates, but the event is not an immediate financial catalyst. Aveanna conference announcement
• Negative Sentiment: Major shareholders, including Bain Capital- and J.H. Whitney-affiliated holders, disclosed substantial sales in a roughly $176 million offering. Additional sales by CEO Jeff Shaner, director Rodney Windley, and insider Edwin Reisz at $11.50 per share could weigh on sentiment and increase concerns about selling pressure, even though these holders retained sizable positions. Home Health Care News offering report

Hedge Funds Weigh In On Aveanna Healthcare

Several hedge funds have recently bought and sold shares of AVAH. Dynamic Technology Lab Private Ltd raised its position in Aveanna Healthcare by 8.9% during the third quarter. Dynamic Technology Lab Private Ltd now owns 14,149 shares of the company’s stock valued at $126,000 after purchasing an additional 1,151 shares in the last quarter. Barclays PLC boosted its holdings in shares of Aveanna Healthcare by 0.8% in the 3rd quarter. Barclays PLC now owns 179,359 shares of the company’s stock valued at $1,591,000 after purchasing an additional 1,366 shares in the last quarter. Franklin Resources Inc. increased its stake in shares of Aveanna Healthcare by 4.5% in the 3rd quarter. Franklin Resources Inc. now owns 35,630 shares of the company’s stock valued at $316,000 after purchasing an additional 1,528 shares during the last quarter. Intech Investment Management LLC increased its stake in shares of Aveanna Healthcare by 9.8% in the 4th quarter. Intech Investment Management LLC now owns 19,483 shares of the company’s stock valued at $159,000 after purchasing an additional 1,739 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of Aveanna Healthcare by 252.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,351 shares of the company’s stock worth $27,000 after buying an additional 2,400 shares in the last quarter. 87.96% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on AVAH. Barclays raised their target price on shares of Aveanna Healthcare from $9.00 to $9.50 and gave the stock an “overweight” rating in a report on Thursday, July 9th. UBS Group increased their price target on Aveanna Healthcare from $8.00 to $13.00 and gave the stock a “neutral” rating in a research report on Friday, August 14th. Wall Street Zen downgraded Aveanna Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 15th. Royal Bank Of Canada raised their price objective on Aveanna Healthcare from $10.00 to $16.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, Truist Financial lifted their price objective on Aveanna Healthcare from $11.00 to $15.00 and gave the company a “hold” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $12.89.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.